ethyl 3-chloro-9H-imidazo[1,5-a][1,2,4]triazolo-[1,5-d][1,4]benzodiazepine-10-carboxylate | 147004-99-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: ethyl 3-chloro-9H-imidazo[1,5-a][1,2,4]triazolo-[1,5-d][1,4]benzodiazepine-10-carboxylate
• 英文别名: Ethyl 15-chloro-2,4,8,9,11-pentazatetracyclo[11.4.0.02,6.08,12]heptadeca-1(13),3,5,9,11,14,16-heptaene-5-carboxylate
• CAS: 147004-99-7
• 化学式: C₁₅H₁₂ClN₅O₂
• 分子量: 329.746
• InChiKey: PPAPIXRCRCPGPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  74.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 3-chloro-9H-imidazo[1,5-a][1,2,4]triazolo-[1,5-d][1,4]benzodiazepine-10-carboxylate 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 2.5h， 以100%的产率得到3-chloro-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine-10-carboxylic acid
  参考文献：
  名称：

  New Tetracyclic Derivatives of Imidazo[1,5-a][1,4]benzodiazepines and of Imidazo[1,5-a]-thieno[3,2-f][1,4]-diazepines

  摘要：

  The synthesis of new tetracyclic 1,4-diazepine derivatives is described. In these compounds, an additional five-membered heterocycle is fused on the known tricyclic ring systems imidazo[1,5-a][1,4]benzodiazepine and imidazo[1,5-a]thieno[3,2-f][1,4]diazepine. Many of these new compounds display a very high affinity to the benzodiazepine receptor in mammals.

  DOI：

  10.3987/com-94-s(b)61
• 作为产物：
  描述：

  3-chloro-5H-[1,2,4]triazolo[1,5-d][1,4]benzodiazepin-6(7H)-one 生成 ethyl 3-chloro-9H-imidazo[1,5-a][1,2,4]triazolo-[1,5-d][1,4]benzodiazepine-10-carboxylate
  参考文献：
  名称：

  Imidazodiazepine derivatives

  摘要：

  翻译结果如下： 所述的咪唑二氮䓬衍生物的公式为：##STR1##，其中取代基如说明书中所述，可用于控制或预防癫痫发作、焦虑、紧张和兴奋状态、睡眠障碍、精神分裂症症状、肝性脑病和老年痴呆症，以及部分或完全拮抗在过量使用或在其在重症医学和麻醉中使用后作用于苯二氮䓬受体的物质的副作用。

  公开号：

  US05387585A1

文献信息

• Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives
  申请人：Knust Henner

  公开号：US20060079507A1

  公开（公告）日：2006-04-13

  The present invention is concerned with a method of treating a disease selected from the group consisting of cognitive disorders, anxiety, Alzheimer's disease, and schizophrenia comprising administering a therapeutically effective amount of a substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives of the following formula wherein R 1 is halogen, lower alkyl, lower alkynyl, cycloalkyl, lower alkoxy, OCF 3 , —NHR, —NHC(O)R or —NHSO 2 R; R 2 is hydrogen, methyl or aryl which is unsubstituted or substituted by one or two substituents selected from the group consisting of halogen and lower alkoxy; R 3 is hydrogen, lower alkyl, lower alkenyl, cycloalkyl, lower alkoxy, —O(CH 2 ) n+1 —O-lower alkyl, —(CH 2 ) n -aryl which is optionally substituted by lower alkyl or halogen, heteroaryl, —NHR, —N(R) 2 , wherein each R can be the same or different, —NHCH 2 C≡CH, or pyrrolidin-1-one; R is hydrogen, lower alkyl, lower alkyl substituted by halogen, heteroaryl, —(CH 2 ) n O-lower alkyl, —NH-lower alkyl, cycloalkyl or aryl, and n is 0, 1, 2 or 3; and with their pharmaceutically acceptable acid addition salts. The invention also provides novel compounds of formula I-A and pharmaceutical compositions containing them. The most preferred indication is Alzheimer's disease.

  本发明涉及一种治疗从认知障碍、焦虑、阿尔茨海默病和精神分裂症中选择的疾病的方法，包括给予下列公式的取代咪唑[1,5-a][1,2,4]三唑[1,5-d][1,4]苯二氮䓬啉衍生物的治疗有效量：其中R1是卤素、较低烷基、较低炔基、环烷基、较低烷氧基、OCF3、—NHR、—NHC(O)R或—NHSO2R；R2是氢、甲基或芳基，未取代或由卤素和较低烷氧基中选择的一种或两种取代基取代；R3是氢、较低烷基、较低烯基、环烷基、较低烷氧基、—O(CH2)n+1—O-较低烷基、—(CH2)n-芳基，可由较低烷基或卤素取代，杂芳基、—NHR、—N(R)2，其中每个R可以相同也可以不同，—NHCH2C≡CH，或吡咯烷酮；R是氢、较低烷基、由卤素取代的较低烷基、杂芳基、—(CH2)nO-较低烷基、—NH-较低烷基、环烷基或芳基，n为0、1、2或3；以及其药学上可接受的酸盐。该发明还提供了公式I-A的新化合物和含有它们的药物组合物。最受欢迎的适应症是阿尔茨海默病。
• Substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives
  申请人：Knust Henner

  公开号：US20060084642A1

  公开（公告）日：2006-04-20

  The present invention is concerned with substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives of formula I wherein R 1 is hydrogen, halogen, lower alkyl, lower alkynyl, cycloalkyl, heterocycloalkyl, benzyl, cyano, lower alkoxy, OCF 3 , —NHR, —NHC(O)R or —NHSO 2 R; R 2 is lower alkyl substituted by halogen; R 3 is hydrogen, methyl or aryl; R is lower alkyl, cycloalkyl or aryl; and pharmaceutically acceptable acid addition salts thereof. Such compounds have a high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders, anxiety, schizophrenia or Alzheimer's disease.

  本发明涉及公式I的取代咪唑[1,5-a][1,2,4]三唑并[1,5-d][1,4]苯二氮平衍生物，其中R1为氢、卤素、较低烷基、较低炔基、环烷基、杂环烷基、苄基、氰基、较低烷氧基、OCF3、—NHR、—NHC(O)R或—NHSO2R；R2为卤素取代的较低烷基；R3为氢、甲基或芳基；R为较低烷基、环烷基或芳基；以及其药学上可接受的酸盐。这些化合物对GABA A α5受体结合位点具有高亲和力和选择性，并可能用作认知增强剂或用于治疗认知障碍、焦虑、精神分裂症或阿尔茨海默病。
• IMIDAZO-BENZODIAZEPINE DERIVATIVES
  申请人：F.Hoffmann-La Roche AG

  公开号：EP1805184B1

  公开（公告）日：2013-01-09
• US5387585A
  申请人：——

  公开号：US5387585A

  公开（公告）日：1995-02-07
• US7514426B2
  申请人：——

  公开号：US7514426B2

  公开（公告）日：2009-04-07